Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-623
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABBV-623 is an orally bioavailable small molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), developed by AbbVie for the treatment of B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia. By binding to and inhibiting Bcl-2, ABBV-623 promotes apoptosis in malignant cells, exhibiting potential pro-apoptotic and antineoplastic activities. Clinical development included phase 1 trials as monotherapy and in combination with other agents for patients with relapsed or refractory B-cell cancers; however, development has been discontinued[1][2][3][4].
02
Targets
BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on ABBV-623.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-623.